Respiratory Weekly News – July 4th 2025 Lung & Respiratory Breakthroughs: ALYFTREK Approval, IPF Trial Milestones, PAH Advancements and more   This week on Lung and Respiratory […] The post Respiratory Weekly News – July 4th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Respiratory Weekly News – July 4th 2025 #News #biotech #Shionogi #cysticfibrosis #BioVersys Comment below!

From Lab Bench to Bell Ring – Marc Gitzinger on BioVersys' road to IPO Marc Gitzinger's path with BioVersys didn't begin on the trading floor—it began in the Swiss startup trenches. As a student at ETH Zurich, he joined the Venture Challenge semester course in 2007 to le...

Exciting journey from bio-technological innovation at @ethz.ch to a successful company: read the inspiring interview with our alumnus Marc Gitzinger, CEO of D-BSSE spinoff company #Bioversys 👇🏽

www.venturelab.swiss/From-Lab-Ben...

Respiratory Weekly News – July 4th 2025 Lung & Respiratory Breakthroughs: ALYFTREK Approval, IPF Trial Milestones, PAH Advancements and more   This week on Lung and Respiratory […] The post Respiratory Weekly News – July 4th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Respiratory Weekly News – July 4th 2025 #News #biotech #Shionogi #cysticfibrosis #BioVersys Comment below!

Respiratory Weekly News – July 4th 2025 Lung & Respiratory Breakthroughs: ALYFTREK Approval, IPF Trial Milestones, PAH Advancements and more   This week on Lung and Respiratory […] The post Respiratory Weekly News – July 4th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Respiratory Weekly News – July 4th 2025 #News #biotech #Shionogi #cysticfibrosis #BioVersys Comment below!

Japan's #Shionogi has added to its #antibiotics pipeline by partnering a preclinical-stage candidate from Swiss #biotech #BioVersys, which specialises in drugs that can counter antimicrobial resistance (#AMR).

pharmaphorum.com/news/shionog...

Basel-based BioVersys made Switzerland's first IPO of the year today, listing on the SIX Swiss Exchange at CHF36.50 ($40.25) per share – giving it a market cap of CHF216M. 📈💰

Shares dipped slightly to CHF36 in the first hour, with 47,000 shares changing hands early on. #Biotech #IPO #BioVersys

The Expanding Landscape of Tuberculosis Treatments: Industry Insights from the Latest Pipeline Report Explore the robust advancements in tuberculosis treatments as over 30 pharmaceutical companies participate in the clinical trial pipeline for TB therapies. Discover recent developments and key players shaping the future of TB treatment.

The Expanding Landscape of Tuberculosis Treatments: Industry Insights from the Latest Pipeline Report #USA #Las_Vegas #GlaxoSmithKline #Tuberculosis #BioVersys